• Phase III READY-3 study met its co-primary endpoints, with RelabotulinumtoxinA significantly improving both frown lines and crow’s feet when treated alone or simultaneously¹
• Results demonstrate high patient satisfaction at one month and long duration of effect for six months¹
• Data further reinforce Relab

Leading Acne Brand Aims to Educate Consumers and Share the Experience of Consistently Clear Skin Through Giveaway of 5,000 Differin Gel Products

• EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040

• Galderma set to commercialize EPSOLAY in the U.S. under exclusive license

• Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation¹
• Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle^1-3